Nuvilex Executives in Southeast Asia To Further Advance Cell-in-a-Box Technology
November 21 2014 - 9:30AM
InvestorsHub NewsWire
SILVER SPRING, MD -
November 21, 2014 - InvestorsHub NewsWire - Nuvilex, Inc. (OTCQB:
NVLX), a clinical-stage biotechnology company providing cell
therapy solutions for the treatment of diseases, announced today
Nuvilex’s Chief Executive Officer, Kenneth L. Waggoner, and Chief
Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to
finalize the Diabetes Consortium that will develop a treatment for
insulin dependent diabetes, to negotiate an additional worldwide,
exclusive license to use Cell-in-a-Box® live cell
encapsulation with cannabinoids to treat diseases and related
symptoms and to tour the new facilities of Austrianova in
Singapore. Mr. Waggoner and Dr. Crabtree will also be attending the
grand opening of the cGMP (current Good Manufacturing Practices)
facility in Thailand where the cells required for Nuvilex’s
preclinical and clinical trials will be encapsulated using the
Cell-in-a-Box® technology.
Mr. Waggoner and Dr. Crabtree visited Austrianova’s headquarters at
Biopolis, Singapore today. As well as viewing Austrianova’s current
lab and office space in Centros, they viewed the new, larger
facility in Synapse, part of the newly built Phase 3 of Biopolis,
where Austrianova will take up residence on December 1, 2014. The
new state-of-the-art laboratory and office space has been custom
built for Austrianova.
Biopolis, which just celebrated its 11th anniversary,
has established a reputation as a world-class biomedical research
hub and has established Singapore as a center of scientific
excellence. As such, Biopolis plays a pivotal role in bringing
together major research institutes to create a center of excellence
in the biomedical sciences and serves as a focal point to attract
and groom top scientific talent to do world-class research in
Singapore. As part of the Singapore visit, Mr. Waggoner and Dr.
Crabtree also met with some of Austrianova’s key shareholders to
further develop the close relationship between the two companies
and to emphasize and establish additional common goals shared by
both entities.
Discussions are scheduled to finalize a number of new and existing
projects, both at the scientific and commercial level. They will
involve participation of academic colleagues from around the
globe.
Dr. Brian Salmons, CEO of Austrianova said, “This multipurpose
meeting has been extremely important in setting the course for the
next year, as well as aligning the aims and goals of all parties
involved. It has been a pleasure to host Mr. Waggoner and Dr.
Crabtree in Southeast Asia and to welcome them to our facilities in
Singapore and Thailand”. Mr. Waggoner stated, “This has been a very
rewarding trip, and we look forward in the coming days to bring to
fruition the plans we have discussed during our visit.”
About Nuvilex
Nuvilex (OTCQB:
NVLX) is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's treatment for pancreatic cancer involves the well-known
anticancer prodrug ifosfamide, together with encapsulated live
cells, which convert ifosfamide into its active or "cancer-killing"
form. Nuvilex is also working towards improving the quality of life
for patients with advanced pancreatic cancer and on treatments for
other types of solid cancerous tumors. In addition, Nuvilex is
developing treatments for cancer based upon chemical constituents
of marijuana known as cannabinoids. Nuvilex is examining ways to
exploit the benefits of Cell-in-a-Box® technology in
optimizing the anticancer effectiveness of cannabinoids, while
minimizing or outright eliminating the debilitating side effects
usually associated with cancer treatments. This provides Nuvilex a
unique opportunity to develop “green” approaches to fighting deadly
cancers, such as those of the pancreas, brain and breast, which
affect hundreds of thousands of individuals worldwide every
year.
Safe
Harbor
This press release may
contain forward-looking statements regarding Nuvilex and its future
events and results that involve inherent risks and uncertainties.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"plan" and similar expressions, as they relate to Nuvilex or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of Nuvilex,
that could cause actual results to differ materially from those set
forth in the forward-looking statements include Nuvilex's ability
to continue as a going concern, delays or unsuccessful results in
clinical trials or flaws or defects regarding its product
candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of Nuvilex's intellectual
property and Nuvilex's continued ability to raise capital. Nuvilex
does not assume any obligation to update any of these
forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmatschullat@bplifescience.com